GlaxoSmithKline PLC (NYSE:GSK) shares saw unusually-high trading volume on Friday . Approximately 2,423,045 shares changed hands during trading, a decline of 1% from the previous session’s volume of 2,456,452 shares.The stock last traded at $44.26 and had previously closed at $42.98.

GSK has been the subject of several recent analyst reports. Citigroup Inc. restated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, June 23rd. Jefferies Group raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Thursday, July 14th. Cowen and Company lowered shares of GlaxoSmithKline PLC from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 26th. Deutsche Bank AG reaffirmed a “hold” rating on shares of GlaxoSmithKline PLC in a research note on Monday, June 27th. Finally, Beaufort Securities reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Tuesday, June 21st. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $47.19.

The firm has a 50 day moving average price of $44.26 and a 200-day moving average price of $42.20. The company has a market cap of $107.57 billion and a P/E ratio of 2766.25.

The business also recently disclosed a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Friday, August 12th will be paid a dividend of $0.494 per share. The ex-dividend date of this dividend is Wednesday, August 10th.

Other hedge funds and institutional investors recently bought and sold shares of the company. US Bancorp DE increased its position in GlaxoSmithKline PLC by 6.1% in the fourth quarter. US Bancorp DE now owns 384,500 shares of the pharmaceutical company’s stock worth $15,514,000 after buying an additional 22,162 shares in the last quarter. Dimensional Fund Advisors LP increased its position in GlaxoSmithKline PLC by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,255,017 shares of the pharmaceutical company’s stock worth $50,640,000 after buying an additional 59,355 shares in the last quarter. Finally, BlackRock Advisors LLC increased its position in GlaxoSmithKline PLC by 2,368.8% in the fourth quarter. BlackRock Advisors LLC now owns 345,182 shares of the pharmaceutical company’s stock worth $13,928,000 after buying an additional 331,200 shares in the last quarter.

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.